Bayer to offload Alzheimer’s imaging agent as part of restructuring?
This article was originally published in Scrip
Bayer HealthCare is reportedly looking to sell its investigational Alzheimer’s imaging agent florbetaben, as part of efforts to restructure its contrast agent and diagnostics businesses. According to the Financial Times Deutschland, the company plans to create a new subunit combining its contrast agents with its imaging subsidiary Medrad, which develops devices to diagnose and treat cardiovascular diseases. The company would not comment to Scrip about the speculation.